A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer

Conditions:   COVID-19;   Sars-CoV2;   Cancer;   Solid Tumor;   Carcinoma;   Blood Cancer Interventions:   Drug: Part 1 - TL-895;   Drug: Part 2 - TL-895;   Drug: Part 2 - Placebo Sponsor:   Telios Pharma, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials